Crinetics Pharmaceuticals (CRNX) stock
CRNX · Crinetics Pharmaceuticals Inc. · NASDAQ
What is the latest news on CRNX stock?
13D/Gago
Amendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.
SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
All CRNX newsWhen does Crinetics Pharmaceuticals report earnings?
Crinetics Pharmaceuticals last reported on Aug 4, 2026, the date it announced on Jun 30, 2026. Before that it reported on May 7, 2026 and Feb 26, 2026.
CRNX earnings historyAre insiders buying or selling CRNX?
No CRNX insider has reported a purchase or sale in the last 90 days. The last trade on file: Coelho Rogerio Vivaldi sold $120K, reported on Jul 7, 2026.
CRNX insider tradesLatest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- SECSEC Form 15-12G filed by Crinetics Pharmaceuticals Inc.15-12G - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- INSIDERDirector Vivaldi Coelho Rogerio returned $1,634,125 worth of shares to the company (19,225 units at $85.00), closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Wierenga Wendell returned $10,376,035 worth of shares to the company (122,071 units at $85.00), closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Okey Stephanie returned $1,047,625 worth of shares to the company (12,325 units at $85.00), closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Fust Matthew K returned $2,444,685 worth of shares to the company (28,761 units at $85.00), closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Nichols Weston returned $1,889,125 worth of shares to the company (22,225 units at $85.00), closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Deardorf Caren returned $1,889,125 worth of shares to the company (22,225 units at $85.00), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Bedrosian Camille L returned $1,889,125 worth of shares to the company (22,225 units at $85.00), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERChief Commercial Officer Kalofonos Isabel returned $3,031,865 worth of shares to the company (35,669 units at $85.00), closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERChief Scientific Officer Betz Stephen F. returned $11,724,560 worth of shares to the company (137,936 units at $85.00), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERChief Financial & Infra. Ofcr. Schilke Tobin returned $6,751,295 worth of shares to the company (79,427 units at $85.00), closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERPresident & CEO Struthers Richard Scott returned $119,247,435 worth of shares to the company (1,402,911 units at $85.00), closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form POSASR filed by Crinetics Pharmaceuticals Inc.POSASR - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
News · 26 weeks66+100%
2026-05-312026-11-22
Mix3190d
- Insider12(39%)
- SEC Filings11(35%)
- Other4(13%)
- 13D/G3(10%)
- Leadership1(3%)
Activity · 52 weeks12956 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Crinetics Pharmaceuticals Inc. (CRNX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for CRNX, including 3 13D/G filings. The most recent was published Nov 16, 2026.
CRNX FAQ
7 questionsWhat does Crinetics Pharmaceuticals Inc. do?
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide...Where does CRNX stock trade?
Crinetics Pharmaceuticals Inc. (CRNX) is listed on NASDAQ.What sector and industry is CRNX in?
Crinetics Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Crinetics Pharmaceuticals Inc. go public?
Crinetics Pharmaceuticals Inc. (CRNX) completed its IPO in 2018.What are analysts saying about CRNX?
Across the last 8 analyst actions on Crinetics Pharmaceuticals Inc., there were 2 upgrades and 0 downgrades. The most recent action was from UBS: Buy with a $55.00 price target on 2026-07-02. Recent price targets range from $36.00 to $68.00.What companies are similar to CRNX?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), ABT (Abbott Laboratories), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare CRNX side-by-side with any of them on Quantisnow.How can I track CRNX on Quantisnow?
Quantisnow aggregates Crinetics Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRNX to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change